Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for non-infectious intermediate, posterior or panuveitis in Chinese adults
CTR20221441Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in uveitis, sponsored by AbbVie Inc.. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
uveitis
Beyond the preview
Go deeper on CTR20221441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221441.